MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
Rhea-AI Summary
MetaVia (Nasdaq: MTVA), a clinical-stage biotech focused on cardiometabolic diseases, will present an update on its pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET.
The virtual event will feature a presentation by senior management followed by a Q&A session, with an archived webcast available later on MetaVia's website.
Positive
- None.
Negative
- None.
News Market Reaction – MTVA
In the Jun 4 session, MTVA declined 8.58%, reflecting a notable negative market reaction. Argus tracked a peak move of +41.9% during that session. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Phase 1 obesity data | Positive | +12.5% | Higher-dose Phase 1 DA-1726 results with weight and liver improvements in obesity. |
| May 20 | Preclinical MASH data | Positive | +47.9% | Peer-reviewed vanoglipel data supporting anti-fibrotic activity and biomarker benefits. |
| May 18 | Conference presentation plan | Positive | +0.0% | Announcement of three late-breaking posters at ADA 2026 on DA-1726 and vanoglipel. |
| May 14 | Q1 2026 earnings update | Neutral | -6.7% | First quarter 2026 financials and updates on DA-1726 and vanoglipel programs. |
| May 11 | EASL poster announcement | Positive | -4.6% | Planned late-breaking Phase 1 DA-1726 poster at EASL Congress 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clearly positive clinical and preclinical updates often coincided with strong upside moves, while some event- or earnings-related news saw flat or negative reactions, indicating selective market enthusiasm for data-heavy catalysts.
Over the last few weeks, MetaVia has repeatedly highlighted its cardiometabolic pipeline. On May 27, higher-dose Phase 1 results for DA-1726 in obesity showed meaningful weight and waist reductions with supportive liver signals, and shares rose 12.46%. A May 20 publication on vanoglipel’s anti-fibrotic potential in MASH preceded a 47.9% gain. Earlier in May, announcements about upcoming ADA and EASL presentations, as well as first-quarter 2026 financial results and trial progress, drew mixed to negative price reactions. Today’s conference appearance continues this pattern of frequent visibility updates alongside developing clinical data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
After the presentation, MetaVia's management will open the floor for questions. Attendees may submit questions in advance to questions@emerginggrowth.com, or ask questions live during the event.
Please register using this link to attend the virtual conference and receive event updates. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.
If unable to join the event live, an archived webcast will be available on the events page of the MetaVia website.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-conference-302790822.html
SOURCE MetaVia Inc.